ArticleBMJ global health2020
Article in BMJ global health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evolution of Pfdhps and Pfdhfr mutations before and after adopting seasonal malaria chemoprevention in Nanoro, Burkina Faso.Scientific reports · 2024Pooled it
- Trial
- Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone.Gates open research · 2025Trial
- A randomized, open-label two-period crossover pilot study to evaluate the relative bioavailability in the fed state of atovaquone-proguanil (Atoguanil™) versus atovaquone-proguanil hydrochloride (Malarone®) in healthy adult participants.Naunyn-Schmiedeberg's archives of pharmacology · 2024Trial
- A cluster randomized trial of delivery of intermittent preventive treatment of malaria in pregnancy at the community level in Malawi.Malaria journal · 2022Trial
- Changes in molecular markers of Plasmodium falciparum drug resistance between 2017 and 2024 in Southern Benin.International journal for parasitology. Drugs and drug resistance · 2026Article
- Ensemble Machine Learning for Malaria Diagnosis in Resource-Limited Settings Using Clinical and Demographic Features.Infectious disease reports · 2026Article
- Identification of an Orally Efficacious Imidazo[4,5-Journal of medicinal chemistry · 2026Article
- Prevalence ofPathogens (Basel, Switzerland) · 2026Article
- National genomic profiling of Plasmodium falciparum antimalarial resistance in Zambian children participating in the 2018 malaria indicator survey.Scientific reports · 2026Article
- Emergence of Plasmodium falciparum pfdhps A581G mutation in Southern Senegal under Seasonal Malaria Chemoprevention pressure, 2020-2023.Communications medicine · 2026Article
- Article
- Emergence of chloroquine-sensitiveEmerging microbes & infections · 2025Article
- Targeted Sequencing Identifies SNPs Associated with Antimalarial Drug Resistance and the CSP Vaccine Antigen inInternational journal of molecular sciences · 2025Article
- Regional variation in sulfadoxine-pyrimethamine resistance genotypes and haplotypes of Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Western Kenya.Malaria journal · 2025Article
- Article
- Impact of dhps mutations on sulfadoxine-pyrimethamine protective efficacy and implications for malaria chemoprevention.Nature communications · 2025Article
- Disparate co-evolution and prevalence of sulfadoxine and pyrimethamine resistance alleles and haplotypes at dhfr and dhps genes across Africa.Scientific reports · 2025Article
- Towards next-generation treatment options to combat Plasmodium falciparum malaria.Nature reviews. Microbiology · 2025Review
- Phase one of a hybrid effectiveness-implementation study to assess the feasibility, acceptability and effectiveness of implementing seasonal malaria chemoprevention in Nampula Province, Mozambique.Malaria journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe rising burden of drug resistance is a major challenge to the global fight against malaria. We estimated national
methodsWe assembled molecular, clinical and endemicity data covering malaria-endemic African countries up to December 2018. Subsequently, we reconstructed georeferenced patient data, using pfdhps540E and pfdhps581G to measure mid-level and high-level SP resistance. Gaussian process regression was applied to model spatiotemporal standardised prevalence.
resultsIn eastern Africa, mid-level SP resistance increased by 64.0% (95% uncertainty interval, 30.7%-69.8%) in Tanzania, 55.4% (31.3%-65.2%) in Sudan, 45.7% (16.8%-54.3%) in Mozambique, 29.7% (10.0%-45.2%) in Kenya and 8.7% (1.4%-36.8%) in Malawi from 2000 to 2010. This was followed by a steady decline of 76.0% (39.6%-92.6%) in Sudan, 65.7% (25.5%-85.6%) in Kenya and 17.4% (2.6%-37.5%) in Tanzania from 2010 to 2020. In central Africa, the levels increased by 28.9% (7.2%-62.5%) in Equatorial Guinea and 85.3% (54.0%-95.9%) in the Congo from 2000 to 2020, while in the other countries remained largely unchanged. In western Africa, the levels have remained low from 2000 to 2020, except for Nigeria, with a reduction of 14.4% (0.7%-67.5%) and Mali, with an increase of 7.0% (0.8%-25.6%). High-level SP resistance increased by 5.5% (1.0%-20.0%) in Malawi, 4.7% (0.5%-25.4%) in Kenya and 2.0% (0.1%-39.2%) in Tanzania, from 2000 to 2020.
conclusionUnder the WHO protocols, SP is no longer effective for intermittent preventive treatment in pregnancy and infancy in most of eastern Africa and parts of central Africa. Strengthening health systems capacity to monitor drug resistance at subnational levels across the endemicity spectrum is critical to achieve the global target to end the epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.